Literature DB >> 30121842

Expression level of NUAK1 in human nasopharyngeal carcinoma and its prognostic significance.

Jiaoyang Liu1, Guoyan Tang1, He Huang2, Huan Li3, Peng Zhang3, Lihua Xu4,5.   

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC) is notable for its high incidence rates in select geographic and ethnic populations, especially among Chinese and Malay populations in Southeastern Asia. However, relevant biomarkers for the development and prognosis of NPC are not yet clear; therefore, discovering novel biomarkers will facilitate prediction of prognosis and development of targeted therapeutic tactics. This study aims to quest the potential prognostic value of NUAK1 (a downstream member of Akt) in NPC.
METHODS: Immunohistochemistry was performed to measure the expression of NUAK1 in paraffin-embedded NPC samples. Statistical analysis, encompassing chi-square tests and Student's t test, was also employed to evaluate the association between the expression of NUAK1 and clinicopathologic features. In addition, the survival analysis was used to detect the prognostic significance of NUAK1 in NPC.
RESULTS: Excessive expression of NUAK1 was found in NPC tissues at mRNA levels. Statistical analysis revealed a correlation of NUAK1 expression with maximum neck lymph node diameter (p = 0.025) and WHO histological type (p = 0.021). Furthermore, according to survival analysis, there was clinical relevance between the upregulation of NUAK1 in NPC and DFS. Subgroup analysis indicated that the expression of NUAK1 was strongly associated with DFS (p = 0.027) and OS (p = 0.026) duration in the patients of N1-3 tumors, but not in patients with N0 tumors. The expression of NUAK1 was also strongly associated with OS (p = 0.044) and DFS (p = 0.007) in patients of late stage tumour (UICC3-5), but not in patients of early stage tumour (UICC1-2). In addition, COX regression illustrated that N classification and NUAK1 expression were independent prognostic factors for disease-free survival.
CONCLUSION: Our study postulated that NUAK1 is excessively expressed in NPC and may serve as a potential predictor of prognosis for NPC.

Entities:  

Keywords:  NUAK1; Nasopharyngeal carcinoma; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30121842     DOI: 10.1007/s00405-018-5095-0

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  25 in total

1.  Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein.

Authors:  Atsushi Suzuki; Gen-Ichi Kusakai; Atsuhiro Kishimoto; Jie Lu; Tsutomu Ogura; Martin F Lavin; Hiroyasu Esumi
Journal:  J Biol Chem       Date:  2002-10-29       Impact factor: 5.157

2.  ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation.

Authors:  Atsushi Suzuki; Gen-Ichi Kusakai; Atsuhiro Kishimoto; Jie Lu; Tsutomu Ogura; Hiroyasu Esumi
Journal:  Oncogene       Date:  2003-09-18       Impact factor: 9.867

3.  ONCOMINE: a cancer microarray database and integrated data-mining platform.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

4.  Expression and clinical significance of LRRC4 in benign and malignant nasopharyngeal diseases.

Authors:  X-J Zhou; Y Wang; L-J Zhang; J-H Chen
Journal:  Genet Mol Res       Date:  2015-12-09

5.  Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.

Authors:  Markus Riester; Wei Wei; Levi Waldron; Aedin C Culhane; Lorenzo Trippa; Esther Oliva; Sung-Hoon Kim; Franziska Michor; Curtis Huttenhower; Giovanni Parmigiani; Michael J Birrer
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

6.  Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model.

Authors:  Cristian A Lasagna-Reeves; Maria de Haro; Shuang Hao; Jeehye Park; Maxime W C Rousseaux; Ismael Al-Ramahi; Paymaan Jafar-Nejad; Luis Vilanova-Velez; Lauren See; Antonia De Maio; Larissa Nitschke; Zhenyu Wu; Juan C Troncoso; Thomas F Westbrook; Jianrong Tang; Juan Botas; Huda Y Zoghbi
Journal:  Neuron       Date:  2016-10-06       Impact factor: 17.173

7.  N,N'-dinitrosopiperazine-mediated AGR2 is involved in metastasis of nasopharyngeal carcinoma.

Authors:  Yuejin Li; Jinping Lu; Zhengke Peng; Gongjun Tan; Na Liu; Damao Huang; Zhenlin Zhang; Chaojun Duan; Xiaowei Tang; Faqing Tang
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

8.  Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma.

Authors:  Bo You; Ying Shan; Si Shi; Xingyu Li; Yiwen You
Journal:  Cancer Sci       Date:  2015-10-14       Impact factor: 6.716

9.  Nasopharyngeal carcinoma incidence and mortality in China, 2013.

Authors:  Kuang-Rong Wei; Rong-Shou Zheng; Si-Wei Zhang; Zhi-Heng Liang; Zhu-Ming Li; Wan-Qing Chen
Journal:  Chin J Cancer       Date:  2017-11-09

10.  Chromodomain Helicase/ATPase DNA-Binding Protein 1-Like Gene (CHD1L) Expression and Implications for Invasion and Metastasis of Breast Cancer.

Authors:  Qing-Jie Mu; Hong-Li Li; Yuan Yao; Shi-Chao Liu; Chong-Gao Yin; Xue-Zhen Ma
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more
  9 in total

1.  Screening of key miRNAs and evaluation of their diagnostic and prognostic values in nasopharyngeal carcinoma.

Authors:  Xianlu Zhuo; Wei Zhou; Huiping Ye; Dairong Li; Aoshuang Chang; Yongzhong Wu; Qi Zhou
Journal:  Oncol Lett       Date:  2019-04-09       Impact factor: 2.967

2.  LINC00958 Promotes The Malignancy Of Nasopharyngeal Carcinoma By Sponging microRNA-625 And Thus Upregulating NUAK1.

Authors:  Meijuan Chen; Zhina Xu; Yingyao Zhang; Xiujuan Zhang
Journal:  Onco Targets Ther       Date:  2019-11-06       Impact factor: 4.147

3.  Implication of hsa_circ_0028007 in reinforcing migration, invasion, and chemo-tolerance of nasopharyngeal carcinoma cells.

Authors:  Dong Qiongna; Zhang Jiafeng; Hao Yalin; He Ping; Zhou Chuan; Jin Xiaojie; Zhao Miaomiao; Shao Yiting; Zhao Hui
Journal:  J Clin Lab Anal       Date:  2020-06-11       Impact factor: 2.352

4.  LncRNA NEAT1/miR-204/NUAK1 Axis is a Potential Therapeutic Target for Non-Small Cell Lung Cancer.

Authors:  Ming-Ming Zhao; Lin-Yang Ge; Liang-Feng Yang; Hai-Xia Zheng; Gang Chen; Li-Zheng Wu; Shao-Ming Shi; Nan Wang; Yan-Ping Hang
Journal:  Cancer Manag Res       Date:  2020-12-29       Impact factor: 3.989

Review 5.  NUAK Kinases: Brain-Ovary Axis.

Authors:  Ester Molina; Linda Hong; Ilana Chefetz
Journal:  Cells       Date:  2021-10-15       Impact factor: 6.600

6.  The Role of hsa-miR-21 and Its Target Genes Involved in Nasopharyngeal Carcinoma.

Authors:  Thuan Duc Lao; Minh Trong Quang; Thuy Ai Huyen Le
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

7.  DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.

Authors:  Xianxiong Ma; Jiancheng Cheng; Peng Zhao; Lei Li; Kaixiong Tao; Hengyu Chen
Journal:  J Cell Mol Med       Date:  2020-06-12       Impact factor: 5.310

8.  miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase.

Authors:  Francesca Maria Orlandella; Raffaela Mariarosaria Mariniello; Peppino Mirabelli; Anna Elisa De Stefano; Paola Lucia Chiara Iervolino; Vito Alessandro Lasorsa; Mario Capasso; Rosa Giannatiempo; Maria Rongo; Mariarosaria Incoronato; Francesco Messina; Marco Salvatore; Andrea Soricelli; Giuliana Salvatore
Journal:  Br J Cancer       Date:  2020-05-18       Impact factor: 7.640

9.  Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities.

Authors:  Yiran Chen; Xiaoling Xie; Chunsheng Wang; Yuxing Hu; Honghao Zhang; Lenghe Zhang; Sanfang Tu; Yanjie He; Yuhua Li
Journal:  Cell Death Dis       Date:  2020-09-01       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.